Background Nonalcoholic fatty disease (NAFLD) is the most common liver disease, since it
is strongly associated with obesity and metabolic syndrome pandemics. NAFLD may affect …

Aim: Liver damage due to facultative hepatotoxins is scarcely foreseeable. We evaluated the
prevalence of acute drug‐induced liver injury (DILI) in a specific setting, assessing eventual …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in developed
countries. Its frequency is increasing in the general population mostly due to the widespread …

Obesity is commonly associated with nonalcoholic fatty liver (NAFL), a benign condition
characterized by hepatic lipid accumulation. However, NAFL can progress in some patients …

Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts
global health in epidemic proportions, and the resulting morbidity, mortality and economic …

Drug-induced liver injury (DILI) is a common and underestimated cause of liver disease.
Several drugs and other xenobiotics can be the cause of different clinicopathologic patterns …

Over the past decades, many drugs have been identified, that can potentially induce
steatohepatitis in the predisposed individual. Classically this has been incriminated to …

Many countries are facing an epidemic of obesity that can be explained, at least in part, by a
sedentary life style and calorie overconsumption. This poses a major issue for public health …

End-stage liver disease (ESLD) is a rare but often fatal complication of nonalcoholic fatty
liver disease (NAFLD). In NAFLD, insulin resistance, which is clinically defined as the …

Introduction: Drug induced steatohepatitis (DISH), a form of drug induced liver injury (DILI) is
characterized by intracellular accumulation of lipids in hepatocytes and subsequent …